VIDEX (didanosine) by Bristol Myers Squibb is [ see clinical pharmacology () ]. First approved in 1991.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
VIDEX (didanosine) is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved in 1991 for HIV treatment. It works by inhibiting reverse transcriptase, blocking viral replication in HIV-infected patients. The drug represents an early-generation antiretroviral with historical significance in HIV therapy evolution.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating reduced commercial investment and team contraction likely underway.
[ see Clinical Pharmacology () ].
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on VIDEX offers limited career growth due to its LOE-approaching lifecycle and minimal linked job openings (0 identified). Career progression would primarily involve cost management, compliance, and supporting healthcare providers managing existing patient populations rather than driving innovation or market expansion.